Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4895 - Potential biomarkers of response to DKK1 blockade with DKN-01 in combination with paclitaxel in advanced esophagogastric cancer (EGC) patients (pts)


11 Sep 2017


Poster display session


Cytotoxic Therapy;  Clinical Research;  Translational Research;  Oesophageal Cancer;  Gastric Cancer


Dan Duda


Annals of Oncology (2017) 28 (suppl_5): v22-v42. 10.1093/annonc/mdx363


D.G. Duda1, C. Sirard2

Author affiliations

  • 1 Radiation Oncology, Massachusetts General Hospital, 02114 - Boston/US
  • 2 Clinical Development, Leap Therapeutics, Inc., 02141 - Cambridge/US


Abstract 4895


Overexpression of DKK1, a modulator of canonical WNT signaling, is frequently seen in malignant tumors and is often associated with worse survival. Preclinical studies have shown that DKK1 can augment tumorigenesis by promoting angiogenesis as well as enhancing tumor-associated immunosuppression. In this Phase I trial, DKN-01 (a humanized IgG4 monoclonal antibody against DKK1) showed encouraging early efficacy signals when combined with paclitaxel (DP) in EGC pts (Strickler et al., GI ASCO 2017). We performed correlative studies of plasma biomarkers of angiogenesis and inflammation in these pts.


Blood samples were collected from 34 patients treated with DP at baseline, and then weekly for 4 weeks (w). Plasma biomarkers were measured by multiplexed array for angiogenesis (bFGF, PIGF/PGF, sVEGFR1, sTIE-2, VEGF, VEGF-C, and VEGF-D) and inflammation (IFN-g, TNF-a, IL-1b, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70 and IL-13) (Meso-Scale Discovery) and by ELISA for HGF and SDF-1a (R&D Systems). Biomarker changes were evaluated by Wilcoxon Sign-Rank test, and correlations with response using Kendall’s test values and with survival using two-sided Wald test in the Cox regression.


Six of 34 EGC pts in this subset analysis (18%) had a PR and 11/34 (32%) showed SD with preliminary median PFS and OS of 13.7w and 28.4w, respectively. DP treatment induced significant and sustained increases in plasma IFN-g, IL-8, VEGF-D and decreases in IL-10 (all p  1 all time-points) and prolonged in pts with greater increases in IL-2 and VEGF-D after treatment.


Prospective plasma biomarker analyses showed that DP treatment changed biomarkers of systemic immunity and angiogenesis in EGC pts, and indicated potential associations between inflammation biomarkers and outcomes. These hypothesis-generating results will inform future prospective investigation of these plasma biomarkers as well as paired evaluation of tumor biopsies for this combination regimen.

Clinical trial identification

Clinical trial information: NCT02013154

Legal entity responsible for the study

Leap Therapeutics, Inc.


Leap Therapeutics, Inc.


D.G. Duda: Consultant fees from Bayer and research funding from Leap Therapeutics, Inc, Merrimack, Bristol-Myers Squibb and Bayer. C. Sirard: Employee of Leap Therapeutics, Inc. (salary and stock options for compensation).

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.